Intravesical valrubicin in the treatment of carcinoma in situ of the bladder.

@article{Kuznetsov2001IntravesicalVI,
  title={Intravesical valrubicin in the treatment of carcinoma in situ of the bladder.},
  author={Dimitri D Kuznetsov and Nejd F Alsikafi and R Corey O'connor and Gary D. Steinberg},
  journal={Expert opinion on pharmacotherapy},
  year={2001},
  volume={2 6},
  pages={1009-13}
}
The propensity of patients with carcinoma in situ (CIS) of the bladder to progress to invasive and metastatic disease is clearly established. Today, the standard therapy in treating patients with CIS of the bladder is intravesical bacillus Calmette-Guerin (BCG). Nevertheless, patients who fail intravesical BCG have few viable options except to undergo a radical cystectomy. Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a new semisynthetic derivative of the anthracycline antibiotic… CONTINUE READING

Similar Papers

Loading similar papers…